Clinical trials: Advanced Solid Tumors Patients
Advanced or Recurrent Solid Tumors, Breast Neoplasm
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose
- Trial name
- NCT03426254
- Testing
- Injections Subcutaneously Talazoparib, Oral capsules Talazoparib
- Where
- Albania
- Sponsor
- Center Trials & Treatment
Advanced Solid Tumor
PBMC-based Leukocyte Immunotherapy
This is an open-label, multicenter, dose-escalation Phase Ib trial of APN401, a suspension of viable Peripheral Blood Mononuclear Cells (PBMCs) from an individual patient that have been transfected with a small interfering…
- Trial name
- PALINDROM (NCT06172894)
- Testing
- APN401
- Where
- 4 sites in Austria
- Volunteers
- 10 people
- Sponsor
- invIOs GmbH
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
This phase I/II trial is studying the side effects and best dose of everolimus when given together with sorafenib tosylate and to see how well they work in treating patients with advanced solid tumors and metastatic pancreatic…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00981162
- Testing
- sorafenib tosylate, everolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the…
- Conditions
- Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma
- Trial name
- NCT05092373
- Testing
- Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
A Study of GFH018 in Patients With Advanced Solid Tumors
This is the first- in human study of GFH018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration.
- Trial name
- NCT05051241
- Testing
- GFH018
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
Advanced Solid Tumors
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
This study is designed to evaluate the response of several biomarkers in patients treated with ARQ 501. The results of the study may help the sponsor understand the effect of the study drug on these biomarkers and their…
- Trial name
- NCT00524524
- Testing
- ARQ 501
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Advanced Solid Malignancies
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily…
- Trial name
- NCT00669097
- Testing
- TKI258
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma
The Oncopanel Pilot (TOP) Study
The BCCA Oncopanel is a clinical assay being developed to determine genotype status of a prospectively defined set of genes. The purpose of this pilot study is to assess the feasibility and effect on clinical-decision-making of…
- Conditions
- Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma, Advanced Melanoma, Gastrointestinal Stromal Tumors
- Trial name
- NCT02171286
- Where
- 5 sites in Canada
- Volunteers
- 432 people
- Sponsor
- British Columbia Cancer Agency
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Tumor, Solid
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
- Trial name
- NCT04819373
- Testing
- BDB001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Eikon Therapeutics
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04282018
- Testing
- BGB-10188, Zanubrutinib, Tislelizumab
- Where
- 24 sites in Australia, China
- Volunteers
- 97 people
- Sponsor
- BeiGene
Advanced Solid Tumors
A Trial of HTI-1090 in Subjects With Advanced Solid Tumors
IDO1 is expressed in a wide variety of human tumors (eg. bladder, breast, colon, DLBCL, HNSCC, lung, ovarian, uterine, renal…), and contributes to tumoral resistance.
- Trial name
- NCT03208959
- Testing
- HTI-1090
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Atridia Pty Ltd.
Urethral Neoplasms, Neoplasms, Urethral
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Background: Gemcitabine and carboplatin are chemotherapy drugs used to treat several types of cancer, including cancer of the pancreas, bladder, ovaries, and lung.
- Conditions
- Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
- Trial name
- NCT01352962
- Testing
- Gemcitabine, Carboplatin, Lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Metastatic Breast Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in…
- Trial name
- NCT03950570
- Testing
- Abraxane, ORIN1001
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- Orinove, Inc.
Neoplasms, Solid Tumors
ADC-1013 First-in-Human Study
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or…
- Trial name
- NCT02379741
- Testing
- ADC-1013
- Where
- 5 sites in Denmark, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Alligator Bioscience AB
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat and bortezomib in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00227513
- Testing
- bortezomib, vorinostat
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.